Literature DB >> 27979863

Measure for measure: minimal residual disease in CLL.

Richard F Little1, Lisa M McShane1.   

Abstract

Mesh：

Year:  2016        PMID： 27979863      PMCID： PMC5159707          DOI： 10.1182/blood-2016-11-745323

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  Biomarkers and surrogate end points--the challenge of statistical validation.

Authors:  Marc Buyse; Daniel J Sargent; Axel Grothey; Alastair Matheson; Aimery de Gramont
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

Review 2.  Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.

Authors:  Philip A Thompson; William G Wierda
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

3.  Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.

Authors:  Carol Moreno; Neus Villamor; Dolors Colomer; Jordi Esteve; Eva Giné; Ana Muntañola; Elias Campo; Francesc Bosch; Emili Montserrat
Journal:  Blood       Date:  2006-01-31       Impact factor: 22.113

4.  Minimal residual disease is an independent predictor for 10-year survival in CLL.

Authors:  Marwan Kwok; Andy C Rawstron; Abraham Varghese; Paul A S Evans; Sheila J M O'Connor; Chi Doughty; Darren J Newton; Paul Moreton; Peter Hillmen
Journal:  Blood       Date:  2016-10-03       Impact factor: 22.113

Review 5.  The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?

Authors:  Sebastian Böttcher; Michael Hallek; Matthias Ritgen; Michael Kneba
Journal:  Hematol Oncol Clin North Am       Date:  2013-04       Impact factor: 3.722

6.  Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.

Authors:  E L Korn; M C Sachs; L M McShane
Journal:  Ann Oncol       Date:  2015-10-21       Impact factor: 32.976

Review 7.  The 21st century revolution in CLL: Why this matters to patients.

Authors:  Brian Koffman; Andrew Schorr
Journal:  Best Pract Res Clin Haematol       Date:  2016-08-11       Impact factor: 3.020

8.  Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Authors:  Jennifer A Woyach; Kelly Smucker; Lisa L Smith; Arletta Lozanski; Yiming Zhong; Amy S Ruppert; David Lucas; Katie Williams; Weiqiang Zhao; Laura Rassenti; Emanuela Ghia; Thomas J Kipps; Rose Mantel; Jeffrey Jones; Joseph Flynn; Kami Maddocks; Susan O'Brien; Richard R Furman; Danelle F James; Fong Clow; Gerard Lozanski; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2014-01-10       Impact factor: 22.113

9.  Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

Authors:  Sebastian Böttcher; Matthias Ritgen; Kirsten Fischer; Stephan Stilgenbauer; Raymonde M Busch; Günter Fingerle-Rowson; Anna Maria Fink; Andreas Bühler; Thorsten Zenz; Michael Karl Wenger; Myriam Mendila; Clemens-Martin Wendtner; Barbara F Eichhorst; Hartmut Döhner; Michael J Hallek; Michael Kneba
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

10.  Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.

Authors:  Gabor Kovacs; Sandra Robrecht; Anna Maria Fink; Jasmin Bahlo; Paula Cramer; Julia von Tresckow; Christian Maurer; Petra Langerbeins; Günter Fingerle-Rowson; Matthias Ritgen; Michael Kneba; Hartmut Döhner; Stephan Stilgenbauer; Wolfram Klapper; Clemens-Martin Wendtner; Kirsten Fischer; Michael Hallek; Barbara Eichhorst; Sebastian Böttcher
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544
  10 in total
  1 in total

1.  Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia.

Authors:  Stefania Galimberti; Meenakshi Devidas; Ausiliatrice Lucenti; Giovanni Cazzaniga; Anja Möricke; Claus R Bartram; Georg Mann; William Carroll; Naomi Winick; Michael Borowitz; Brent Wood; Giuseppe Basso; Valentino Conter; Martin Zimmermann; Stefan Suciu; Andrea Biondi; Martin Schrappe; Stephen P Hunger; Maria Grazia Valsecchi
Journal:  JNCI Cancer Spectr       Date:  2018-12-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.